Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on August 4, 2021, covering events occurring on August 3 and August 4, 2021. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Charlottesville, Virginia. Its common stock (ADIL) and warrants (ADILW) trade on the NASDAQ.
Key Financial Metrics
The filing details a specific capital raise event rather than providing comprehensive financial statements for a reporting period.
- Capital Raised: $4,500,000 in gross proceeds.
- Shares Issued: 1,500,000 shares of common stock in the "2nd Tranche" of a private offering.
- Price Per Share: $3.00.
- Transaction Costs: No broker fees were incurred.
- Warrants: No warrants were issued in this tranche.
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide clear values for these general financial metrics.
Material Changes
The primary material change is the closing of the second tranche of a private offering of common stock. This transaction followed the effectiveness of a Registration Statement on Form S-3 filed on July 20, 2021. The shares were sold to accredited investors under an exemption from registration requirements (Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D).
The specific allocation of shares was as follows:
- Bespoke Growth Partners, Inc. (controlled by Chief Strategy Officer Mark Peikin): 750,000 shares.
- Keystone Capital Partners, LLC: 450,000 shares.
- Richard Gilliam: 300,000 shares.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclaimers. It notes that the report does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the use of the $4.5 million proceeds as disclosed in subsequent filings or press releases.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or rights granted to the investors.
- Check for any related party transaction disclosures regarding the investment by Bespoke Growth Partners, Inc., controlled by the Company's Chief Strategy Officer.